LatestNews

OMass Announces Publication in Nature Methods
May 15, 2020

Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…

Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
February 25, 2020

– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…

Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
February 17, 2020

– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…

Read More
OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal
July 23, 2019

Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today…

Read More